Cochrane · systematic review · CD011203
Alemtuzumab for multiple sclerosis
Riera, R, Torloni, MR, Martimbianco, ALC, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 1 · 8.3%Low 9 · 75%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsAlemtuzumab 12 mg compared to interferon beta‐1a for multiple sclerosis
Population: adults with relapsing–remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse‐free survival Alemtuzumab 12 mg vs interferon beta‐1a | HR 0.31 [0.18, 0.53] | 1 study · 221 participants | Low Downgraded: risk of bias |
Sustained disease progression‐free survival Alemtuzumab 12 mg vs interferon beta‐1a | HR 0.25 [0.11, 0.56] | 1 study · 223 participants | Low Downgraded: risk of bias |
Adverse events, including serious events Assessed by: number of participants with ≥ 1 event Alemtuzumab 12 mg vs interferon beta‐1a | RR 1 [0.98, 1.02] | 1 study · 224 participants | Low Downgraded: risk of bias |
Change in disability Assessed by: EDSS Alemtuzumab 12 mg vs interferon beta‐1a | no estimate extracted | 1 study · 223 participants | Low Downgraded: risk of bias |
New or enlarging T2‐hyperintense lesions Assessed by: number of participants with new or enlarging T2‐hyperintense lesions Alemtuzumab 12 mg vs interferon beta‐1a | no estimate extracted | NR | No studies |
Dropouts Assessed by: number of participants who dropped out Alemtuzumab 12 mg vs interferon beta‐1a | RR 0.81 [0.57, 1.14] | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision |
Alemtuzumab 24 mg compared to interferon beta‐1a for multiple sclerosis
Population: adults with multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse‐free survival Alemtuzumab 24 mg vs interferon beta‐1a | HR 0.21 [0.11, 0.4] | 1 study · 221 participants | Low Downgraded: risk of bias |
Sustained disease progression‐free survival Alemtuzumab 24 mg vs interferon beta‐1a | HR 0.33 [0.16, 0.69] | 1 study · 221 participants | Low Downgraded: risk of bias |
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event Alemtuzumab 24 mg vs interferon beta‐1a | RR 0.99 [0.97, 1.02] | 1 study · 215 participants | Low Downgraded: risk of bias |
Change in disability Assessed by: EDSS Alemtuzumab 24 mg vs interferon beta‐1a | no estimate extracted | 1 study · 221 participants | Low Downgraded: risk of bias |
New or enlarging T2‐hyperintense lesions Alemtuzumab 24 mg vs interferon beta‐1a | no estimate extracted | NR | No studies |
Dropouts Alemtuzumab 24 mg vs interferon beta‐1a | RR 0.08 [0.01, 0.57] | 1 study · 215 participants | Low Downgraded: risk of bias |